Immunitybio Inc (IBRX)

Jun 3, 2025, 8:45 AM EDT - 3 days ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 2, 2025, 9:00 AM EDT - 4 days ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

May 27, 2025, 8:00 AM EDT - 10 days ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 12, 2025, 6:30 AM EDT - 26 days ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 5, 2025, 5:05 PM EDT - 4 weeks ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 9:21 AM EDT - 4 weeks ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 6:30 AM EDT - 4 weeks ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

Apr 29, 2025, 12:50 PM EDT - 5 weeks ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 28, 2025, 8:30 AM EDT - 5 weeks ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 21, 2025, 4:21 PM EDT - 6 weeks ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 7 weeks ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 8, 2025, 7:30 AM EDT - 2 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 7, 2025, 5:00 AM EDT - 2 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 3, 2025, 5:54 PM EDT - 2 months ago

ImmunityBio: Taking Care Of Business

Mar 26, 2025, 6:00 AM EDT - 2 months ago

ImmunityBio to Host Investor Day

Mar 13, 2025, 9:00 AM EDT - 3 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 7, 2025, 1:47 AM EST - 3 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 3, 2025, 7:30 AM EST - 3 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Feb 27, 2025, 7:10 PM EST - 3 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 19, 2025, 9:00 AM EST - 3 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 13, 2025, 3:05 PM EST - 4 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 29, 2025, 8:30 AM EST - 4 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 27, 2025, 9:00 AM EST - 4 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 17, 2025, 2:05 PM EST - 5 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 16, 2025, 2:25 PM EST - 5 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 15, 2025, 5:20 PM EST - 5 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 5 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 6, 2025, 9:00 AM EST - 5 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Dec 16, 2024, 12:24 AM EST - 6 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 13, 2024, 2:40 PM EST - 6 months ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 12, 2024, 8:00 AM EST - 6 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 11, 2024, 7:30 AM EST - 6 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 6 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Nov 21, 2024, 10:00 AM EST - 7 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 19, 2024, 9:00 AM EST - 7 months ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 8:00 AM EST - 7 months ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Nov 12, 2024, 7:15 AM EST - 7 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

Oct 28, 2024, 7:53 AM EDT - 7 months ago

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Oct 25, 2024, 8:22 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

SRRK

Oct 24, 2024, 9:00 AM EDT - 8 months ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Oct 23, 2024, 3:35 PM EDT - 8 months ago

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

Oct 21, 2024, 9:00 AM EDT - 8 months ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Oct 7, 2024, 11:18 AM EDT - 8 months ago

ImmunityBio: Moving The Needle

Sep 21, 2024, 7:02 PM EDT - 9 months ago

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 9, 2024, 8:30 AM EDT - 9 months ago

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Aug 16, 2024, 7:57 AM EDT - 10 months ago

Top 3 Health Care Stocks That Are Set To Fly This Quarter

HAE PGNY

Aug 14, 2024, 2:13 PM EDT - 10 months ago

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 12, 2024, 8:46 AM EDT - 10 months ago

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Aug 6, 2024, 9:00 AM EDT - 10 months ago

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer